You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

CLINICAL TRIALS PROFILE FOR UROLOGIC G IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Urologic G In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003930 ↗ Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed National Cancer Institute (NCI) Phase 1/Phase 2 1999-09-01 RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00003930 ↗ Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed Radiation Therapy Oncology Group Phase 1/Phase 2 1999-09-01 RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00132301 ↗ Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Completed Sanofi Phase 3 2006-06-01 VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
NCT00132301 ↗ Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Completed VA Office of Research and Development Phase 3 2006-06-01 VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Urologic G In Plastic Container

Condition Name

Condition Name for Urologic G In Plastic Container
Intervention Trials
Prostate Cancer 9
Bladder Cancer 6
Pain, Postoperative 6
Urologic Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Urologic G In Plastic Container
Intervention Trials
Pain, Postoperative 14
Urinary Bladder Neoplasms 10
Syndrome 7
Prostatic Neoplasms 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Urologic G In Plastic Container

Trials by Country

Trials by Country for Urologic G In Plastic Container
Location Trials
United States 215
Japan 25
Canada 19
Korea, Republic of 8
Egypt 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Urologic G In Plastic Container
Location Trials
New York 14
California 13
Michigan 10
Texas 10
Maryland 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Urologic G In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Urologic G In Plastic Container
Clinical Trial Phase Trials
Phase 4 45
Phase 3 18
Phase 2 15
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Urologic G In Plastic Container
Clinical Trial Phase Trials
Completed 52
Recruiting 21
Not yet recruiting 17
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Urologic G In Plastic Container

Sponsor Name

Sponsor Name for Urologic G In Plastic Container
Sponsor Trials
University of Texas Southwestern Medical Center 4
Yonsei University 4
National Cancer Institute (NCI) 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Urologic G In Plastic Container
Sponsor Trials
Other 154
Industry 26
NIH 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Urologic Solutions in Plastic Containers

Introduction

Urologic solutions, particularly those packaged in plastic containers, are crucial in the management and treatment of various urological conditions. This article will delve into recent clinical trials, market analysis, and future projections for these solutions.

Clinical Trials Update

d-Mannose for Urinary Tract Infections

A recent randomized clinical trial investigated the efficacy of d-mannose in preventing recurrent urinary tract infections (UTIs) in women. The trial, conducted across 99 primary care centers in the UK, involved 598 women who were randomized to either d-mannose or a placebo for 6 months. The results showed that d-mannose did not significantly reduce the proportion of women experiencing medically attended UTIs compared to the placebo group[1].

This study highlights the importance of rigorous clinical trials to establish the effectiveness of potential prophylactic treatments for common urological conditions like UTIs.

Market Analysis

Urology Disposable Market

The urology disposable market is a significant segment within the broader healthcare industry. This market includes products such as urine catheters, urine collection bags, and male external catheters. Here are some key points from the market analysis:

  • Market Size and Growth: The global urology disposable market is expected to grow substantially, driven by the increasing prevalence of urological illnesses such as cystitis, urinary retention, and kidney stones. The market size is projected to increase due to rising demand from diagnostic laboratories, healthcare facilities, and other end-use applications[5].

  • Product Segments: The market is segmented into various product types, including urine catheters, urine collection bags, and male external catheters. Each segment is expected to see growth driven by technological advancements and the increasing need for these products in both hospital and home care settings[5].

  • Geographical Distribution: The market is geographically diverse, with North America, Europe, and the Asia-Pacific region being key contributors. The North American market is particularly dominant due to its well-developed infrastructure and strong supply chain network[5].

Specimen Containers Market

The specimen containers market, which includes containers for urine samples, is also growing. Here are some key points:

  • Market Size and Growth Rate: The global specimen containers market was valued at USD 2.0 billion in 2021 and is expected to expand at a CAGR of 4.85% from 2022 to 2030. This growth is driven by the increasing prevalence of chronic diseases, trauma cases, and technological advancements[2].

  • Demand Drivers: The demand for specimen containers is driven by the need for safe and efficient transport and collection of patient samples, including urine. The rising prevalence of urological illnesses further fuels this demand[2].

Projections and Future Trends

Technological Advancements

Technological advancements are expected to play a crucial role in the future growth of the urology disposable and specimen containers markets. Innovations in material science, such as the development of stronger and more airtight containers, will enhance product integrity and safety. Digital technology integration in clinical trials and healthcare settings will also drive market expansion[2][3].

Regulatory Compliance

Ensuring compliance with strict regulations, such as those set by the U.S. Food and Drug Administration (FDA) and Health Canada, will remain a critical factor. Companies must adhere to safety features, labeling, and tracking protocols to maintain market credibility and avoid regulatory hurdles[3].

Customized Packaging

The trend towards customized packaging solutions is expected to create new opportunities in the market. Patients' ease of use and safety are key drivers, and companies that can offer tailored packaging solutions will likely see increased demand[3].

Key Takeaways

  • Clinical Trials: Recent trials, such as the d-mannose study, highlight the need for rigorous testing to establish the efficacy of urologic treatments.
  • Market Growth: The urology disposable and specimen containers markets are expected to grow significantly, driven by increasing urological illnesses and technological advancements.
  • Technological Advancements: Innovations in materials and digital technology will enhance product safety and efficiency.
  • Regulatory Compliance: Adherence to strict regulations is crucial for market success.
  • Customized Solutions: Tailored packaging solutions will drive future market growth.

FAQs

Q1: What was the outcome of the d-mannose clinical trial for preventing UTIs? The trial found that d-mannose did not significantly reduce the proportion of women experiencing medically attended UTIs compared to the placebo group[1].

Q2: What is driving the growth of the urology disposable market? The market is driven by the increasing prevalence of urological illnesses, technological advancements, and rising demand from healthcare facilities and diagnostic laboratories[5].

Q3: How is the specimen containers market expected to grow? The specimen containers market is expected to grow at a CAGR of 4.85% from 2022 to 2030, driven by the increasing prevalence of chronic diseases and technological advancements[2].

Q4: What role do regulatory compliance and technological advancements play in the market? Regulatory compliance is crucial for maintaining market credibility, while technological advancements in materials and digital technology will enhance product safety and efficiency[3].

Q5: What trend is expected to create new opportunities in the urology disposable market? The trend towards customized packaging solutions is expected to create new opportunities, driven by patients' ease of use and safety[3].

Sources

  1. JAMA Internal Medicine: "d-Mannose for Prevention of Recurrent Urinary Tract Infection in Women: A Randomized Clinical Trial"[1]
  2. Grand View Research: "Specimen Containers Market Size, Share Report, 2022 - 2030"[2]
  3. GlobeNewswire: "Clinical Trial Packaging Market Size Expected to Reach USD 9.12 Billion by 2034"[3]
  4. Baxter PI: "3% Sorbitol Urologic Irrigating Solution"[4]
  5. IndustryARC: "Urology Disposable Market - Forecast(2024 - 2030)"[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.